1. Yamogenin in fenugreek inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes
- Author
-
Hiroki Murakami, Nobuyuki Takahashi, Tsuyoshi Goto, Keiko Taketani, Taku Uemura, Shohei Hoshino, Nobuaki Tsuge, Sayaka Moriwaki, Toshihiko Narukami, and Teruo Kawada
- Subjects
Male ,Diosgenin ,Applied Microbiology and Biotechnology ,Biochemistry ,Analytical Chemistry ,chemistry.chemical_compound ,Mice ,medicine ,Animals ,Humans ,RNA, Messenger ,Liver X receptor ,Molecular Biology ,Fatty acid synthesis ,Triglycerides ,Yamogenin ,Liver X Receptors ,chemistry.chemical_classification ,biology ,Organic Chemistry ,Fatty Acids ,Fatty acid ,General Medicine ,Hep G2 Cells ,Lipid Metabolism ,Orphan Nuclear Receptors ,Sterol ,Fatty acid synthase ,medicine.anatomical_structure ,Trigonella ,chemistry ,Gene Expression Regulation ,Hepatocyte ,biology.protein ,Hepatocytes ,Sterol Regulatory Element Binding Protein 1 ,Biotechnology - Abstract
Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek. Here, we examined the effects of yamogenin on the accumulation of triacylglyceride (TG) in hepatocytes, because yamogenin is also contained in fenugreek. It was demonstrated that yamogenin also inhibited TG accumulation in HepG2 hepatocytes and suppressed the mRNA expression of fatty acid synthesis-related genes such as fatty acid synthase and sterol response element-binding protein-1c. Indeed, yamogenin also antagonized the activation of the liver X receptor (LXR) in luciferase ligand assay similar to diosgenin. However, yamogenin could not exert such effects in the presence of T0901713, a potent agonist of LXR. These findings indicate that the effects of yamogenin on TG accumulation would be weaker than those of diosgenin, suggesting that the structural difference between yamogenin and diosgenin would be important for the inhibition of LXR activation.
- Published
- 2014